Kymera Therapeutics Inc
NASDAQ:KYMR
Intrinsic Value
Kymera Therapeutics, Inc. operates as a biotechnology company, which engages in curing untreatable diseases. [ Read More ]
The intrinsic value of one KYMR stock under the Base Case scenario is 15.674 USD. Compared to the current market price of 32.845 USD, Kymera Therapeutics Inc is Overvalued by 52%.
Valuation Backtest
Kymera Therapeutics Inc
Run backtest to discover the historical profit from buying and selling KYMR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Kymera Therapeutics Inc
Current Assets | 405.3m |
Cash & Short-Term Investments | 374.9m |
Receivables | 18.8m |
Other Current Assets | 11.7m |
Non-Current Assets | 170.4m |
Long-Term Investments | 61.4m |
PP&E | 101.1m |
Other Non-Current Assets | 7.9m |
Current Liabilities | 85.7m |
Accounts Payable | 7.1m |
Accrued Liabilities | 35.2m |
Other Current Liabilities | 43.4m |
Non-Current Liabilities | 95.1m |
Long-Term Debt | 1.3m |
Other Non-Current Liabilities | 93.8m |
Earnings Waterfall
Kymera Therapeutics Inc
Revenue
|
78.6m
USD
|
Operating Expenses
|
-244.1m
USD
|
Operating Income
|
-165.5m
USD
|
Other Expenses
|
18.6m
USD
|
Net Income
|
-147m
USD
|
Free Cash Flow Analysis
Kymera Therapeutics Inc
KYMR Profitability Score
Profitability Due Diligence
Kymera Therapeutics Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
Score
Kymera Therapeutics Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
KYMR Solvency Score
Solvency Due Diligence
Kymera Therapeutics Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Score
Kymera Therapeutics Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
KYMR Price Targets Summary
Kymera Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for KYMR is 52.255 USD with a low forecast of 30.3 USD and a high forecast of 117.6 USD.
Ownership
KYMR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
KYMR Price
Kymera Therapeutics Inc
Average Annual Return | 9.55% |
Standard Deviation of Annual Returns | 73.56% |
Max Drawdown | -88% |
Market Capitalization | 1.8B USD |
Shares Outstanding | 58 521 837 |
Percentage of Shares Shorted | 16.62% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Kymera Therapeutics, Inc. operates as a biotechnology company, which engages in curing untreatable diseases. The company is headquartered in Watertown, Massachusetts. The company went IPO on 2020-08-21. The firm is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Its targeted protein degradation (TPD) platform Pegasus, allows it to discover selective small molecule protein degraders with activity against disease-causing proteins throughout the body. The Company’s Pegasus platform includes E3 Ligase Whole-Body Atlas, E3 Ligase Binders Toolbox, Ternary Complex Modeling, Quantitative System Pharmacology Model and Chemistry. Its clinical stage programs include IRAK4, IRAKIMiD, and STAT3, which each address targets within the interleukin-1 receptor/toll-like receptor (IL-1R/TLR), and janus kinase/signal transducers and activators of transcription (JAK/STAT). Its programs focus on treating range of immune-inflammatory diseases, hematologic malignancies, and solid tumors.
Contact
IPO
Employees
Officers
The intrinsic value of one KYMR stock under the Base Case scenario is 15.674 USD.
Compared to the current market price of 32.845 USD, Kymera Therapeutics Inc is Overvalued by 52%.